179 related articles for article (PubMed ID: 34269158)
21. Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.
Long Y; Gao Z; Hu X; Xiang F; Wu Z; Zhang J; Han X; Yin L; Qin J; Lan L; Yin F; Wang Y
Cancer Med; 2018 Sep; 7(9):4690-4700. PubMed ID: 30051648
[TBL] [Abstract][Full Text] [Related]
22. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.
Pinheiro C; Miranda-Gonçalves V; Longatto-Filho A; Vicente AL; Berardinelli GN; Scapulatempo-Neto C; Costa RF; Viana CR; Reis RM; Baltazar F; Vazquez VL
Cell Cycle; 2016 Jun; 15(11):1462-70. PubMed ID: 27105345
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma.
Cheng B; Chen X; Li Y; Huang X; Yu J
Oncol Rep; 2018 Nov; 40(5):2906-2915. PubMed ID: 30226548
[TBL] [Abstract][Full Text] [Related]
24. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
Pinheiro C; Sousa B; Albergaria A; Paredes J; Dufloth R; Vieira D; Schmitt F; Baltazar F
Histol Histopathol; 2011 Oct; 26(10):1279-86. PubMed ID: 21870331
[TBL] [Abstract][Full Text] [Related]
25. ZEB1 induces ROS generation through directly promoting MCT4 transcription to facilitate breast cancer.
Han X; Long Y; Duan X; Liu Z; Hu X; Zhou J; Li N; Wang Y; Qin J
Exp Cell Res; 2022 Mar; 412(2):113044. PubMed ID: 35093305
[TBL] [Abstract][Full Text] [Related]
26. MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells.
Abdellatif AAH; Bouazzaoui A; Tawfeek HM; Younis MA
Colloids Surf B Biointerfaces; 2024 Jun; 238():113930. PubMed ID: 38692174
[TBL] [Abstract][Full Text] [Related]
27. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.
Witkiewicz AK; Whitaker-Menezes D; Dasgupta A; Philp NJ; Lin Z; Gandara R; Sneddon S; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Cell Cycle; 2012 Mar; 11(6):1108-17. PubMed ID: 22313602
[TBL] [Abstract][Full Text] [Related]
28. Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
Gotanda Y; Akagi Y; Kawahara A; Kinugasa T; Yoshida T; Ryu Y; Shiratsuchi I; Kage M; Shirouzu K
Anticancer Res; 2013 Jul; 33(7):2941-7. PubMed ID: 23780984
[TBL] [Abstract][Full Text] [Related]
29. The prognostic significance of the expression of monocarboxylate transporter 4 in patients with right- or left-sided colorectal cancer.
Abe Y; Nakayama Y; Katsuki T; Inoue Y; Minagawa N; Torigoe T; Higure A; Sako T; Nagata N; Hirata K
Asia Pac J Clin Oncol; 2019 Apr; 15(2):e49-e55. PubMed ID: 30270512
[TBL] [Abstract][Full Text] [Related]
30. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
[TBL] [Abstract][Full Text] [Related]
31.
Chou CH; Chiang CF; Yang CC; Liu YC; Chang SR; Chang KW; Lin SC
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769160
[TBL] [Abstract][Full Text] [Related]
32. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes.
Pérez de Heredia F; Wood IS; Trayhurn P
Pflugers Arch; 2010 Feb; 459(3):509-18. PubMed ID: 19876643
[TBL] [Abstract][Full Text] [Related]
34. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression.
Sanità P; Capulli M; Teti A; Galatioto GP; Vicentini C; Chiarugi P; Bologna M; Angelucci A
BMC Cancer; 2014 Mar; 14():154. PubMed ID: 24597899
[TBL] [Abstract][Full Text] [Related]
35. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes.
Vaz CV; Marques R; Alves MG; Oliveira PF; Cavaco JE; Maia CJ; Socorro S
J Cancer Res Clin Oncol; 2016 Jan; 142(1):5-16. PubMed ID: 26048031
[TBL] [Abstract][Full Text] [Related]
36. A Holistic Evolutionary and 3D Pharmacophore Modelling Study Provides Insights into the Metabolism, Function, and Substrate Selectivity of the Human Monocarboxylate Transporter 4 (hMCT4).
Papakonstantinou E; Vlachakis D; Thireou T; Vlachoyiannopoulos PG; Eliopoulos E
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805725
[TBL] [Abstract][Full Text] [Related]
37. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
38. A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.
Hao Q; Huang Z; Li Q; Liu D; Wang P; Wang K; Li J; Cao W; Deng W; Wu K; Su R; Liu Z; Vadgama J; Wu Y
Adv Sci (Weinh); 2022 Feb; 9(6):e2102303. PubMed ID: 35023320
[TBL] [Abstract][Full Text] [Related]
39. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4.
Meijer TW; Schuurbiers OC; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; Verhagen AF; Lok J; van der Heijden HF; Rademakers SE; Span PN; Bussink J
Lung Cancer; 2012 Jun; 76(3):316-23. PubMed ID: 22153830
[TBL] [Abstract][Full Text] [Related]
40. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.
Queirós O; Preto A; Pacheco A; Pinheiro C; Azevedo-Silva J; Moreira R; Pedro M; Ko YH; Pedersen PL; Baltazar F; Casal M
J Bioenerg Biomembr; 2012 Feb; 44(1):141-53. PubMed ID: 22350013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
